(Fighting against new crown pneumonia) China's new crown vaccine research and development "accelerated" is expected to be launched by the end of this year
China News Agency, Beijing, August 23 (Reporter Du Yan) China is accelerating the development of new crown vaccine. Two Chinese companies that produce inactivated vaccines for the new coronavirus said in Beijing on the 23rd that they are currently advancing phase III clinical trials of the vaccine and are expected to be launched by the end of this year.
Since the outbreak of the new crown pneumonia, China has adhered to the parallel five technical routes of virus inactivated vaccines, nucleic acid vaccines, recombinant protein vaccines, adenovirus vector vaccines, and attenuated influenza virus vector vaccines to improve vaccine research and development efficiency.
Not only China, but also companies from various countries have invested in the research and development of the new crown vaccine. Experts from the Chinese Center for Disease Control and Prevention revealed on the 21st that 29 vaccines worldwide have entered clinical trials and 138 vaccines are in preclinical studies. Data from the World Health Organization shows that six vaccines have entered the phase III clinical trial phase, of which three are from China.
"At present, China's new bio-coronavirus inactivated vaccine has been successively launched in the UAE, Peru, Morocco and other places." Zhang Yuntao, vice president of China National Biotechnology Co., Ltd., said that the company is vigorously promoting the development of Phase III clinical studies overseas. "We hope , Or it is very likely to be listed at the end of this year."
Compared with traditional vaccine development, the development of new crown vaccines is much faster. In this regard, Zhang Yuntao said that this is due to the fact that inactivated vaccines have formed a good technical accumulation in the early stage, including system research and quality control.
He revealed that after the new crown vaccine production workshops of the company's two research institutes in Beijing and Wuhan are put into use, the total annual output will reach 220 million doses.
Vaccines are considered to be the "killer" to defeat the new crown pneumonia epidemic, and people all over the world are looking forward to it. Yin Weidong, chairman, president and CEO of Kexing Holding Biotechnology Co., Ltd., which developed the new coronavirus inactivated vaccine "Kellaifu", said that phase three clinical trials are being launched in Brazil and Indonesia. Among them, Kerlaifu obtained the clinical research approval from the Indonesian Drug Administration in July, and started the Phase III clinical enrollment in Bandung, West Java in August; 12 research centers in 6 states in Brazil are recruiting nearly 9,000 Volunteers are expected to complete the enrollment work at the end of September.
"It is expected to be listed at the end of this year." Yin Weidong said that Beijing Kexing Zhongwei Biotechnology Co., Ltd., a subsidiary of Kexing Holding Biotechnology Co., Ltd., launched the new crown virus inactivated vaccine industrialization project at the end of March this year. It is located in Daxing District, Beijing. The square meter vaccine plant will be put into trial production before the end of August, and will form an annual production capacity of more than 300 million doses.
China has made a clear commitment that after the successful development of China's new crown vaccine, it will become a global public product. So, what is the future market pricing of the new crown vaccine? In this regard, Yin Weidong said that the new crown vaccine is a public health product, and its availability must be considered. “We will work hard to get the Chinese vaccine to market as soon as possible, so that the general public will benefit as soon as possible.” (Finish)